Unilever's new ice-cream-free era does not impress all analysts

Unilever completed the demerger of its tea, coffee and ice-cream arm (Magnum Ice Cream Company) last weekend, but UBS remains negative—keeping a 'sell' rating and cutting its 12-month price target to 4,440p (from 4,635p), implying an 8.4% downside to the current ~4,847p share price—citing subdued market volume growth and earnings dilution from the separation. Management reiterated medium-term mid-single-digit underlying sales growth, Q4 volume guidance at least in line with Q3’s 1.7% and H2 operating margin ex-ice-cream of at least 19.5%, while warning that current market volume growth is nearer 1% versus historical norms. Post-demerger, Unilever expects an approximate 10% earnings drag partially offset by share consolidation and €1.5bn annual buybacks (UBS estimates buybacks add ~150bp/year to EPS), and UBS now values the stock at about 17x 2026 earnings, a modest discount to peers.

Analysis

Unilever completed the demerger of its tea, coffee and ice-cream arm (Magnum Ice Cream Company) last weekend and UBS maintained a 'sell' rating, cutting its 12-month price target to 4,440p from 4,635p, implying an 8.4% downside from the current ~4,847p share price. UBS cites subdued market volume growth and earnings dilution from the separation as the drivers of the downgrade.

Management reaffirmed Q4 volume guidance at least in line with Q3’s 1.7% and expects H2 operating margin excluding ice cream to be at least 19.5%, while repeating medium-term mid-single-digit underlying sales ambitions; CEO Fernando Fernandez highlighted the US and India as strategic markets that together represent 35% of turnover. UBS flagged that current market volume growth is nearer 1%, materially below historical norms, which raises execution risk for those medium-term targets.

Post-demerger, Unilever anticipates an approximate 10% earnings drag partially offset by share consolidation and continued €1.5bn annual buybacks, which UBS estimates add ~150 basis points per year to EPS; UBS now values the stock at ~17x 2026 earnings, a slight discount to peers. The near-term balance is therefore between headline EPS pressure and capital return support, making outlook contingent on volume recovery and buyback delivery.

Key Decisions for Investors

• Avoid initiating new long positions until Q4 volume and H2 margin prints confirm management's guidance or show upside to current assumptions
• Monitor three leading indicators—Q4 volume growth versus the 1.7% guide, H2 operating margin ex-ice-cream versus 19.5%, and market volume trends in the US and India—and use them to reassess conviction
• Consider selective accumulation on meaningful share-price weakness toward UBS's 4,440p target only if buybacks continue at ~€1.5bn and there is clear evidence of stabilizing or improving volumes
• Reduce position size or implement downside hedges to reflect the ~10% post-demerger earnings drag and the risk that market volume growth remains near 1%, keeping multiples under pressure